See more : Cybergun S.A. (ALCYB.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Antibe Therapeutics Inc. (ATBPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Antibe Therapeutics Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Panda Dairy Corporation (300898.SZ) Income Statement Analysis – Financial Results
- Ellington Financial Inc. (EFC-PC) Income Statement Analysis – Financial Results
- Fiserv, Inc. (0IP9.L) Income Statement Analysis – Financial Results
- Experience Co Limited (EXP.AX) Income Statement Analysis – Financial Results
- Pennsylvania Real Estate Investment Trust (PRET) Income Statement Analysis – Financial Results
Antibe Therapeutics Inc. (ATBPF)
About Antibe Therapeutics Inc.
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 9.71M | 9.99M | 9.54M | 8.51M | 9.05M | 4.44M | 19.96K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 99.00K | 6.16M | 6.10M | 5.99M | 5.13M | 5.12M | 2.38M | 150.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -99.00K | 3.55M | 3.89M | 3.55M | 3.38M | 3.93M | 2.06M | -130.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 36.55% | 38.94% | 37.21% | 39.66% | 43.45% | 46.34% | -651.62% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.31M | 14.36M | 13.43M | 8.08M | 3.94M | 2.74M | 700.80K | 407.22K | 2.30M | 1.23M | 262.82K | 214.14K |
| General & Administrative | 8.91M | 10.96M | 11.19M | 8.77M | 7.86M | 3.54M | 6.55M | 3.78M | 1.85M | 1.34M | 755.93K | 728.00K |
| Selling & Marketing | 331.00K | 208.00K | 2.72M | 3.79M | 3.52M | 3.38M | 1.54M | 202.27K | 53.28K | 72.24K | 10.79K | 0.00 |
| SG&A | 9.24M | 11.17M | 13.91M | 12.56M | 11.38M | 6.92M | 8.09M | 3.99M | 1.90M | 1.41M | 755.93K | 728.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 20.55M | 25.53M | 27.81M | 21.21M | 15.74M | 10.04M | 9.14M | 5.23M | 4.42M | 2.67M | 1.02M | 942.14K |
| Cost & Expenses | 20.55M | 25.53M | 33.98M | 27.30M | 21.73M | 15.17M | 14.26M | 7.61M | 4.42M | 2.67M | 1.02M | 942.14K |
| Interest Income | 1.35M | 282.00K | 52.00K | 99.00K | 31.41K | 17.35K | 3.64K | 6.40K | 19.96K | 6.30K | 0.00 | 0.00 |
| Interest Expense | 8.00K | 8.00K | 236.00K | 500.00K | 430.29K | 1.18M | 835.17K | 324.62K | 384.00 | 15.17K | 26.36K | 0.00 |
| Depreciation & Amortization | 99.00K | 99.00K | 478.00K | 571.00K | 416.22K | 377.14K | 352.61K | 158.74K | 19.96K | 21.46K | 26.36K | 0.00 |
| EBITDA | -20.45M | -25.15M | -23.73M | -17.98M | -11.84M | -6.15M | -4.92M | -2.99M | -4.40M | -2.66M | -1.02M | -942.14K |
| EBITDA Ratio | 0.00% | 0.00% | -244.33% | -166.68% | -123.08% | -73.67% | -53.59% | -67.95% | -22,053.26% | 0.00% | 0.00% | 0.00% |
| Operating Income | -20.55M | -25.53M | -24.71M | -18.92M | -12.19M | -6.66M | -5.21M | -3.28M | -4.42M | -2.69M | -1.05M | -942.14K |
| Operating Income Ratio | 0.00% | 0.00% | -254.44% | -189.42% | -127.77% | -78.31% | -57.53% | -73.96% | -22,153.26% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.26M | 279.00K | -1.20M | -1.72M | -494.00K | -1.04M | -902.10K | -347.74K | 19.57K | -8.87K | 0.00 | 0.00 |
| Income Before Tax | -19.29M | -25.25M | -24.73M | -19.35M | -12.68M | -7.70M | -6.11M | -3.50M | -4.40M | -2.68M | -1.05M | -942.14K |
| Income Before Tax Ratio | 0.00% | 0.00% | -254.65% | -193.74% | -132.95% | -90.53% | -67.49% | -78.80% | -22,053.26% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 184.00K | -182.00K | 1.80M | -7.00K | 134.13K | -274.76K | -365.00K | -865.20K | 0.00 | 0.00 | 26.36K | 0.00 |
| Net Income | -19.48M | -25.06M | -26.30M | -19.34M | -12.82M | -7.43M | -5.75M | -2.63M | -4.40M | -2.68M | -1.05M | -942.14K |
| Net Income Ratio | 0.00% | 0.00% | -270.78% | -193.67% | -134.36% | -87.31% | -63.46% | -59.30% | -22,053.26% | 0.00% | 0.00% | 0.00% |
| EPS | -0.37 | -0.49 | -0.71 | -0.71 | -0.60 | -0.49 | -0.60 | -0.42 | -1.19 | -1.02 | -0.40 | -0.36 |
| EPS Diluted | -0.37 | -0.49 | -0.71 | -0.71 | -0.60 | -0.49 | -0.60 | -0.42 | -1.19 | -1.02 | -0.40 | -0.36 |
| Weighted Avg Shares Out | 52.29M | 50.77M | 37.25M | 27.27M | 21.49M | 15.16M | 9.57M | 6.27M | 3.69M | 2.62M | 2.61M | 2.61M |
| Weighted Avg Shares Out (Dil) | 52.29M | 50.77M | 37.25M | 27.27M | 21.49M | 15.16M | 9.57M | 6.27M | 3.69M | 2.62M | 2.61M | 2.61M |
Antibe Announces Appointment of Receiver
Antibe Provides Update on CCAA Proceedings
Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act
Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act
Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting
Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma
Antibe Reports Q3 2024 Interim Financial and Operating Results
Antibe Extends Early Warrant Exercise Incentive Program
Antibe Announces Early Warrant Exercise Incentive Program
Antibe Therapeutics Announces Amendment to Warrant Terms
Source: https://incomestatements.info
Category: Stock Reports